Myasthenia Gravis (MG) Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Global Myasthenia Gravis (MG) Treatment Market size is expected to reach USD 2.06 billion by 2028 at a CAGR of 7% during the forecast period 2022-2028.

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder that weakens the skeletal muscles of the arms and legs. Double vision, facial paralysis, difficulty walking, and drooping eyelids are symptoms of myasthenia gravis. The disease is diagnosed with tests such as repeated nerve stimulation tests, blood tests for antibodies, edrophonium tests, computed tomography (CT), and magnetic resonance imaging (MRI). Corticosteroid drugs (azathioprine and cyclosporine) and acetylcholinesterase inhibitors (edrophonium and pyridostigmine) are used to treat MG.

Market Segments

By Medications

• Cholinesterase inhibitors
• Corticosteroids
• Immunosuppressants

By End-User

• Hospital pharmacies
• Retail pharmacies
• Others

Key Players

Major players analyzed include Alexion Pharmaceutical Inc., GlaxoSmithKline plc, Grifols SA, F. Hoffmann-La Roche Ltd, Avadel Pharmaceuticals plc, Pfizer, Inc., Novartis AG, AbbVie Inc., Bausch Health Companies Inc., and Shire plc.

Scope of the Report

The research study analyzes the global Myasthenia Gravis (MG) Treatment industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Myasthenia Gravis (MG) Treatment Market Report

1. What was the Myasthenia Gravis (MG) Treatment Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Myasthenia Gravis (MG) Treatment Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Myasthenia Gravis (MG) Treatment Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.